FIELD: pharmacology.
SUBSTANCE: described are C-6 modified indazolyl pyrrolotriaxolines of formula I 
and their pharmaceutically acceptable salts, where R is selected from group consisting of phenylm phenyl substituted with halogen atom, non-substituted oxazolyl, thienyl, thiazolyl, pyridyl, pyrazinyl; R1 is selected from group consisting of methyl, ethyl and isopropyl; R2 is selected from group consisting of benzyl, imidazolylethyl, (methylimidazolyl)-ethyl, pyperidinylethyl, pyridinylpropyl and other, given in item 1 of invention formula, X is selected from group consisting of bond, O, NR3; and N(R3)2; R3 is independently selected from group consisting of hydrogen, methoxyethyl, diethylaminoethyl, pyrrolidinylethyl. Also described are pharmaceutical composition for treatment of proliferative disease, methods of disease treatment. Compounds of formula I inhibit tyrosine kinase activity of growth factor receptors such as HER1, HER2 and HER4, which makes them useful as anti-cancer agents.
EFFECT: compounds are anti-cancer agents and are useful for treatment of other diseases connected with pathways of signal transduction acting through growth factor receptors.
23 cl, 4 tbl, 175 ex
| Title | Year | Author | Number |
|---|---|---|---|
| PYRROLTRIAZINE KINASE INHIBITORS | 2000 |
|
RU2331640C2 |
| NEW KINASE INHIBITORS | 2003 |
|
RU2331642C2 |
| METHOD FOR TREATMENT OF STATES CAUSED BY p38 KINASES AND PYRROLOTRIAZINE COMPOUNDS USED AS KINASE INHIBITORS | 2001 |
|
RU2316556C2 |
| CONDENSED TRIAZOLAMINES AS P2X7 MODULATORS | 2010 |
|
RU2533122C2 |
| PYRROLOTRIAZINE COMPOUNDS AS KINASE INHIBITORS | 2004 |
|
RU2373209C2 |
| PYRIMIDINE HYDRAZIDE COMPOUNDS AS PGDS INHIBITORS | 2008 |
|
RU2464262C2 |
| CYCLIC INHIBITORS OF PROTEIN-TYROSINE KINASE | 2000 |
|
RU2312860C2 |
| CXCR7 ANTAGONISTS | 2013 |
|
RU2649004C2 |
| PYRROLOTRIAZINE DERIVATIVES AS KINASE INHIBITOR | 2018 |
|
RU2726632C1 |
| BENZOTHIAZOLE INHIBITORS OF PROTEIN TYROSINE KINASES | 1998 |
|
RU2212407C2 |
